RVX000222

DRUG8 trials

Conditions

Acute Coronary SyndromeAtherosclerosisCardiovascular DiseaseCoronary Artery DiseaseDiabetesDyslipidemiaFabry Diseasediabetes mellitus ischemic heart disease

Phase 1

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

CompletedNCT00768274

Resverlogix CorpAcute Coronary Syndrome, Atherosclerosis, Cardiovascular Disease +1

Start: 2008-09-30End: 2009-08-31Updated: 2022-11-04

Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

WithdrawnNCT03228940

Resverlogix CorpFabry Disease

Start: 2022-11-22End: 2022-11-22Updated: 2023-11-18

Phase 2

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

CompletedNCT01058018

Resverlogix CorpAtherosclerosis, Coronary Artery Disease

Start: 2009-12-31End: 2010-09-30Updated: 2023-04-03

ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation

CompletedNCT01067820

Resverlogix CorpCoronary Artery Disease

Start: 2011-09-30End: 2013-06-30Updated: 2013-06-04

The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation

CompletedNCT01423188

Resverlogix CorpCoronary Artery Disease, Dyslipidemia

Start: 2011-08-31End: 2012-08-31Updated: 2012-09-20

The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

CompletedNCT01728467

Resverlogix CorpDiabetes

Start: 2012-11-30End: 2014-03-31Updated: 2014-04-02

Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

TerminatedNCT01863225

Resverlogix CorpCoronary Artery Disease, Dyslipidemia

Start: 2013-05-31End: 2013-06-30Updated: 2015-05-12

Phase 3

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, up to Placebo- Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects with Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment with RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Active, not recruitingNL-OMON47920

Resverlogixdiabetes mellitus ischemic heart disease

Start: 2017-09-20Target: 30Updated: 2024-02-28

Related Papers

The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.

2019-02-0128 citations

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.

2016-02-0179 citations

ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.

2012-04-0168 citations

Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.

2011-01-20132 citations